Profit Warning from Subsidiary: Shanghai Yuyuan, a subsidiary of FOSUN INTL, has issued a profit warning, projecting a net loss of RMB4.8 billion for FY25.

Overall Loss Forecast: Citi estimates that FOSUN INTL will incur a net loss of approximately RMB778 million for FY25, considering the profit warning and forecasts for its other businesses.

Short Selling Activity: FOSUN INTL has experienced significant short selling, amounting to $16.87 million, with a short selling ratio of 32.096%.

Rating and Target Price Adjustment: Despite the negative outlook, Citi maintains a Buy rating on FOSUN INTL but has reduced its target price from HKD6.5 to HKD5.6.

IPO Announcement: GON TECHNOLOGY plans to list in Hong Kong, offering 30 million H-shares, with 10% for public offering and 90% for international placement, aiming to raise approximately HKD1.26 billion.

Offer Price and Subscription Details: The share price ranges from HKD34 to HKD42, with an entry fee of about HKD8,484.71 for one board lot (200 shares). The subscription period runs from January 27 to January 30, with listing expected on February 4.

Net Proceeds Estimation: At a median offer price of HKD38 per share, the net proceeds from the IPO are projected to be around HKD1.0577 billion.

Cornerstone Investors: The IPO includes eight cornerstone investors, such as SLD International and Luminous Horizon, collectively subscribing for shares worth nearly HKD320 million.

Fosun and BYD Partnership: Fosun International and BYD Company have established a global long-term strategic partnership focusing on creating a "Mobility + Vacation" integrated ecosystem leveraging their strengths in green mobility and tourism.

Target Audience and Collaboration: The partnership aims to connect BYD's 15 million car owners with Fosun's 20 million members, fostering deep interconnection through product innovation and ecological interconnection.

Fosun International Participation: Fosun International is participating in the China International Import Expo (CIIE) for the eighth consecutive year, showcasing innovative pharmaceuticals and high-end medical devices at their booth.

Focus on Healthcare Innovation: The company emphasizes its commitment to addressing unmet clinical needs in healthcare, leveraging global industrial advantages to promote cutting-edge technologies in China.

Chairman's Statement: Chairman Guo Guangchang highlighted the CIIE as a platform for China's development and international collaboration, aiming for high-level opening-up and global sharing of public products.

Short Selling Data: Fosun International has reported short selling of $5.45 million with a ratio of 28.397%, while Fosun Pharma has $16.21 million in short selling with a ratio of 16.975%.